top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-1/h4-1BB mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Tnfrsf9tm1(TNFRSF9)Bcgen/Bcgen
Common Name  B-hPD-1/h4-1BB mice
Background C57BL/6 Catalog number  120516
Related Genes 
PD-1 (Programmed death-1) ;
TNFRSF9 
(TNF receptor superfamily member 9, also known as 4-1BB)
NCBI Gene ID
1856621942

mRNA expression analysis


from clipboard


Strain specific analysis of 4-1BB and PD-1 gene expression in B-hPD-1/h4-1BB mice by RT-PCR. Mouse 4-1BB and PD-1 mRNA was detectable in splenocytes of wild-type (+/+) mice. Human 4-1BB and PD-1 mRNA was detectable only in H/H but not in +/+ mice. 

Protein expression analysis

from clipboard


Strain specific 4-1BB expression analysis in homozygous B-hPD-1/h4-1BB mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/h4-1BB (H/H) mice stimulated with or without anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-4-1BB antibody. Mouse 4-1BB was detectable in WT mice. Human 4-1BB was exclusively detectable in homozygous B-hPD-1/h4-1BB but not WT mice.

from clipboard


Strain specific PD-1 expression analysis in homozygous B-hPD-1/h4-1BB mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/h4-1BB (H/H) mice stimulated with or without anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1 antibody. Mouse PD-1 was detectable in WT mice. Human PD-1 was exclusively detectable in homozygous B-hPD-1/h4-1BB but not WT mice.

Analysis of spleen leukocytes cell subpopulations in B-hPD-1/h4-1BB mice

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hPD-1/h4-1BB mice (n=3, 9- week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, NK, Monocyte, DC and macrophage cells in homozygous B-hPD-1/h4-1BB mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1 and h4-1BB in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen.

Analysis of spleen T cell subpopulations in B-hPD-1/h4-1BB mice


from clipboard


Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hPD-1/h4-1BB mice (n=3, 9-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hPD-1/h4-1BB mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1 and h4-1BB in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in spleen. Values are expressed as mean ± SEM.


Analysis of blood leukocytes cell subpopulations in B-hPD-1/h4-1BB mice

from clipboard


Analysis of blood leukocyte subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hPD-1/h4-1BB mice (n=3, 9-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, NK, Monocyte, DC and macrophage cells in homozygous B-hPD-1/h4-1BB mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1 and h4-1BB in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in blood.

Analysis of blood T cell subpopulations in B-hPD-1/h4-1BB mice

from clipboard


Analysis of blood T cell subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hPD-1/h4-1BB mice (n=3, 9-week-old). Flow cytometry analysis of the blood cells was performed to assess blood cell subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hPD-1/h4-1BB mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1 and h4-1BB in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in blood. Values are expressed as mean ± SEM.

Blood routine test in B-hPD-1/h4-1BB mice

from clipboard


Complete blood count (CBC),Blood from female C57BL/6 and B-hPD-1/h4-1BB mice (n=3, 9-week-old) was analyzed with CBC. There was no differences among any measurement between C57BL/6 and B-hPD-1/h4-1BB mice, indicating that introduction of hPD-1 and h4-1BB in place of its mouse counterpart does not change blood cell composition and morphology. Values are expressed as mean ± SEM.

Blood chemistry of B-hPD-1/h4-1BB mice

from clipboard


Blood chemistry tests of B-hPD-1/h4-1BB mice. Serum from the C57BL/6 and B-hPD-1/h4-1BB mice (n=3, 9-week-old) was analyzed for levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). There was no differences on either measurement between C57BL/6 and B-hPD-1/h4-1BB mice, indicating that introduction of hPD-1 and h4-1BB in place of its mouse counterpart does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.

In vivo efficacy of combination of anti-human PD-1 antibody and anti-human 4-1BB antibody

from clipboard


Antitumor activity of combination of anti-human PD-1 antibody and anti-human 4-1BB in B-hPD-1/h4-1BB mice. (A) combination of anti-human PD-1 antibody and anti-human 4-1BB antibody inhibited MC38 tumor growth in B-hPD-1/h4-1BB mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/h4-1BB mice (female, 6-week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human PD-1 antibody and anti-human 4-1BB antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human 4-1BB antibody were efficacious in controlling tumor growth in B-hPD-1/h4-1BB mice, demonstrating that the B-hPD-1/h4-1BB mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human 4-1BB antibody. Values are expressed as mean ± SEM.

In vivo efficacy of combination of anti-human PD-1 antibody and anti-human 4-1BB antibody

from clipboard


Antitumor activity of combination of anti-human PD-1 antibody and anti-human 4-1BB in B-hPD-1/h4-1BB mice. (A) combination of anti-human PD-1 antibody and anti-human 4-1BB antibody inhibited MC38-hPD-L1 tumor growth in B-hPD-1/h4-1BB mice. Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/h4-1BB mice (female, 6-week-old, n=8). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human PD-1 antibody and anti-human 4-1BB antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human 4-1BB antibody were efficacious in controlling tumor growth in B-hPD-1/h4-1BB mice, demonstrating that the B-hPD-1/h4-1BB mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human 4-1BB antibody. Values are expressed as mean ± SEM.

from clipboard


Antitumor activity of combination of anti-human PD-1 antibody and anti-human 4-1BB in B-hPD-1/h4-1BB mice. (A) combination of anti-human PD-1 antibody and anti-human 4-1BB antibody inhibited B16F10-hPD-L1 tumor growth in B-hPD-1/h4-1BB mice. B16F10-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/h4-1BB mice (female, 6-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human PD-1 antibody and anti-human 4-1BB antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human 4-1BB antibody were efficacious in controlling tumor growth in B-hPD-1/h4-1BB mice, demonstrating that the B-hPD-1/h4-1BB mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human 4-1BB antibody. Values are expressed as mean ± SEM.

from clipboard


Antitumor activity of combination of anti-human PD-1 antibody and anti-human 4-1BB in B-hPD-1/h4-1BB mice. (A) combination of anti-human PD-1 antibody and anti-human 4-1BB antibody inhibited EL4 tumor growth in B-hPD-1/h4-1BB mice. EL4 cells were subcutaneously implanted into homozygous B-hPD-1/h4-1BB mice (female, 6-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human PD-1 antibody and anti-human 4-1BB antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human 4-1BB antibody were efficacious in controlling tumor growth in B-hPD-1/h4-1BB mice, demonstrating that the B-hPD-1/h4-1BB mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human 4-1BB antibody. Values are expressed as mean ± SEM.